Fri, Sep 19, 2014, 1:20 PM EDT - U.S. Markets close in 2 hrs 40 mins


% | $
Quotes you view appear here for quick access.

Zalicus Inc. Message Board

  • daugnosall daugnosall Oct 20, 2013 9:06 AM Flag


    why pay 20?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • That may not be a bad thing to happen.

      • 1 Reply to indian2568
      • How a partnership deal might look if both trials succeed.
        Following two successful phase 2a trials, Zalicus Inc. (ZLCS) has entered into a collaboration with Merck & Co., Inc. to develop and commercialize Z160, its first in class, oral, state dependent, selective N-type calcium channel (Cav 2.2) blocker for the treatment of chronic pain, including lumbosacral radiculopathy (LSR), post-herpetic neuralgia (PHN), and other conditions.

        Zalicus, a clinical-stage biopharmaceutical company, will receive an upfront payment of $150 million and up to an additional $825 million in development and regulatory milestone payments. Profits will be split equally between the two companies on a worldwide basis.

        The agreement includes plans to launch several Phase III trials over the next several years. Zalicus will pay for 40% of development costs, while Merck will pay the remainder.

        "We look forward to sharing with Merck the responsibility and accountability for turning our vision for Z160 into an everyday reality. Z160 orphan drug status for PHN will expedite patient access to this remarkable medicine and help fund our efforts going forward." said Zalicus Chief Executive Mark Corrigan, M.D.

        In the U.S., Zalicus will book sales and take a lead role in the treatment's domestic strategy development, though both companies will share in commercialization activities. Outside the U.S., Merck will book sales and lead commercialization activities.

1.18+0.03(+2.61%)Jul 15 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.